QUELL

Live / Registered — Registered (as of 16 Jun 2020)

What this means for you

Registered since 16 Jun 2020. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
88372290
Registration number
6077717
Mark type
Stylized text
Filed
04 Apr 2019
Published for opposition
31 Mar 2020
Registered
16 Jun 2020
Attorney of record
Steven T. Shelton

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; veterinary preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for cell therapy, namely, preparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceutical, medical, and clinical preparations for use in treatment, amelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparations, namely, chimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management
  • Class 040 — Treatment of materials: Manufacturing and processing pharmaceuticals for others; manufacturing and processing biological, biotechnological and biopharmaceutical preparations for others; processing of biological tissue, blood, cell, and genetic material for others; production and manufacture of viral vectors for others; production and manufacture of gene therapy products for others; custom manufacture of pharmaceutical and biological preparations for others; none of the foregoing having any relation to pain treatment or management
  • Class 042 — Scientific and technological services: advisory services relating to gene therapy and design; Scientific and technological services, namely, research and design in the field of T cells with an immunosuppressive phenotype and transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; industrial analysis and research in the field of cell therapy; medical and veterinary research services in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new therapies in the field of autoimmune, immunological disorders and to modulate the immune system; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; scientific and technological services, namely, design in the field of cell therapy; none of the foregoing having any relation to pain treatment or management
  • Class 044 — Medical, beauty and agricultural services: Medical services; medical services in the field of immunology; medical services in the field of surgery; medical services in the field of autoimmune diseases and conditions; medical services, in the field of, tissue transplant surgery; collection and preservation of biological tissue, blood, cells and genetic materials; medical diagnosis of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; Medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; providing information and data for diagnosis and medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; gene and nucleic acid delivery or modification for therapeutic purposes; medical treatment, namely, administering cell or gene therapies; advisory services in the field of health as it relates to cell or gene therapy; medical advisory services relating to cell or gene therapy; none of the foregoing having any relation to pain treatment or management

Owner

Prosecution history

  • 16 Jun 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
  • 25 Jan 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 25 Jan 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 25 Jan 2023 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
  • 25 Jan 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
  • 25 Jan 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
  • 25 Jan 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
  • 16 Jun 2020 — REGISTERED-PRINCIPAL REGISTER
  • 31 Mar 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 31 Mar 2020 — PUBLISHED FOR OPPOSITION
  • 11 Mar 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 25 Feb 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 25 Feb 2020 — EXAMINER'S AMENDMENT ENTERED
  • 25 Feb 2020 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
  • 25 Feb 2020 — EXAMINERS AMENDMENT E-MAILED

View this trademark record on Marksy